Ellen Corliss
Vice President
 Corporate Communications
& Investor Relations
(919) 855-2112

Oxygen Biotherapeutics Reports Financial Results for Fiscal Year 2011

MORRISVILLE, NC, July 14, 2011 — Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXBT), a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced results for the fiscal year (FY) ended April 30, 2011.

R&D Highlights
Completed the first cohort of our STOP-TBI Phase IIb clinical trial and initiated efforts to expand trials to India.  Received DSMB approval to proceed to second cohort of the STOP-TBI Phase IIb clinical trial.
Entered into a Cooperative Research and Development Agreement with the U.S. Naval Medical Research Center to conduct additional preclinical trials to assess the safety and efficacy of Oxycyte for the prevention and treatment of decompression sickness and related injuries.
U.S. Navy studies demonstrated decreased mortality in models that were given an intravenous dose of Oxycyte PFC emulsion after the onset of decompression sickness. This data was published in the June 2010 issue of Aviation Space and Environmental Medicine.
Signed research contract funded by the Department of Defense with Hackensack University Medical Center to study the wound healing properties of Wundecyte™ gel. Studies are underway.
Signed a Letter of Intent with Sarasota Medical Products to pursue joint research and development in chronic ischemic wound care.

Corporate Highlights
Raised $­­4.9 million in a private placement of Unregistered Convertible Notes and Warrants in June 2011.
Received $2.07 million two-year grant from the U.S. Army to study the use of Oxycyte® perfluorocarbon (PFC) emulsion for traumatic brain injury.
Raised nearly $5 million from a registered direct offering in May 2010.

DERMACYTE® Highlights
Launched two oxygenating skin care products, DERMACYTE Concentrate and DERMACYTE Oxygenating Eye Complex in the U.S. via internet sales and direct sales to dermatologists and medi-spas.
Expanded international sales of DERMACYTE by entering into agreements with two distributors that will sell DERMACYTE® skin care products in the Swiss, Mexican, European and Russian markets.
Secured listings on leading on-line beauty retail websites for DERMACYTE skin care products: www.Dermstore.com  and www.Beautyriche.com


The following information was filed by Tenax Therapeutics, Inc. (TENX) on Friday, July 15, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Tenax Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Tenax Therapeutics, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account